Novo Nordisk A

vorige Seite Seite 1 von 8 nächste Seite

Umstellung von anderen Basalinsulinen auf einmal wöchentlich verabreichtes Insulin Icodec hat sich in Phase 2-Studie bei Menschen mit Typ-2-Diabetes als wirkungsvoll und gut verträglich erwiesen

Novo Nordisk gab heute die Ergebnisse von drei klinischen Phase-2-Studien für Insulin Icodec, ein einmal wöchentlich zu verabreichendes Basalinsulin-Analogon, bekannt, die während der 56. Jahrestagung …

24.09.2020 12:29
15.06.2020 01:31

Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged …

31.03.2020 18:01

Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off

Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim …

01.10.2019 19:40

Tresiba® Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower …

19.09.2019 12:03

Oral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels

Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across …

17.09.2019 15:02

Fiasp® Demonstrated Effective Overall Blood Sugar Reductions in People With Advanced Type 2 Diabetes Uncontrolled on Multiple Daily Injections (Basal-bolus Regimen)

New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not …

17.09.2019 10:15

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with …

11.06.2019 20:45

Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks

Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance® (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza® (liraglutide 1.8 mg) …

08.06.2019 17:45

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg).

24.03.2019 14:55

Ozempic® Superior in Lowering Blood Sugar and Weight Vs Placebo, Both in Combination with SGLT-2 Inhibitors

Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.

04.03.2019 14:01

People With Diabetes May Achieve Improved Glycaemic Control With Tresiba® Versus Glargine U100, Without an Increase in Hypoglycaemia

According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba® (insulin degludec) versus insulin …

02.10.2018 12:01

Ryzodeg® Offers a Simpler Solution With Once-Daily Dosing and Reduced Risk of Nocturnal Hypoglycaemia vs Insulin Glargine U100 Plus Insulin Aspart

When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily insulin dose and …

02.10.2018 12:00

Addressing Social and Cultural Drivers of Type 2 Diabetes is Key to Its Treatment and Prevention

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.[1] Researchers …

02.10.2018 12:00
vorige Seite nächste Seite